$2.99 14.6%
NKTX Stock Price vs. AI Score
Data gathered: November 27

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Nkarta (NKTX)

Analysis generated July 12, 2024. Powered by Chat GPT.

Nkarta, Inc. is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies to treat cancer. Their innovative approach to harnessing NK cells positions them as a promising player in the rapidly advancing field of cell therapy. However, as with many biotechnology firms, Nkarta’s financial performance can be volatile given the high research and development costs and the long timelines associated with clinical trials.

Read full AI stock Analysis

Stock Alerts - Nkarta (NKTX)

company logo Nkarta | November 27
Price is up by 6.9% in the last 24h.
company logo Nkarta | November 25
Price is up by 5.7% in the last 24h.
company logo Nkarta | November 15
Price is down by -5.2% in the last 24h.
company logo Nkarta | November 14
Price is down by -5.5% in the last 24h.

About Nkarta

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment.


Nkarta
Price $2.99
Target Price Sign up
Volume 1,530,000
Market Cap $183M
Year Range $2.44 - $12.98
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2408.5M-8.5M-28M-31M0.000
Q2 '2407.6M-7.6M-25M-28M-0.340
Q1 '2409.8M-9.8M-30M-31M-0.580
Q4 '23010M-10M-28M-29M-0.570
Q3 '2307.1M-7.1M-26M-27M-0.520

Insider Transactions View All

Hager Alicia J. filed to sell 103,819 shares at $8.
July 18 '24
Brandenberger Ralph filed to sell 79,743 shares at $5.6.
June 20 '24
Hager Alicia J. filed to sell 107,215 shares at $5.6.
June 20 '24
Shook David filed to sell 116,524 shares at $5.6.
June 20 '24
Trager James filed to sell 150,959 shares at $5.6.
June 20 '24

What is the Market Cap of Nkarta?

The Market Cap of Nkarta is $183M.

What is the current stock price of Nkarta?

Currently, the price of one share of Nkarta stock is $2.99.

How can I analyze the NKTX stock price chart for investment decisions?

The NKTX stock price chart above provides a comprehensive visual representation of Nkarta's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Nkarta shares. Our platform offers an up-to-date NKTX stock price chart, along with technical data analysis and alternative data insights.

Does NKTX offer dividends to its shareholders?

As of our latest update, Nkarta (NKTX) does not offer dividends to its shareholders. Investors interested in Nkarta should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Nkarta?

Some of the similar stocks of Nkarta are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.